Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Return on Capital Employed (2016 - 2025)

Vanda Pharmaceuticals' Return on Capital Employed history spans 15 years, with the latest figure at 37.8% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 3042.0% to 37.8% in Q4 2025 year-over-year; TTM through Dec 2025 was 37.8%, a 3042.0% decrease, with the full-year FY2025 number at 35.37%, down 2801.0% from a year prior.
  • Return on Capital Employed hit 37.8% in Q4 2025 for Vanda Pharmaceuticals, down from 24.46% in the prior quarter.
  • Over the last five years, Return on Capital Employed for VNDA hit a ceiling of 8.77% in Q3 2021 and a floor of 37.8% in Q4 2025.
  • Historically, Return on Capital Employed has averaged 3.7% across 5 years, with a median of 0.57% in 2022.
  • Biggest five-year swings in Return on Capital Employed: surged 409bps in 2021 and later plummeted -3042bps in 2025.
  • Tracing VNDA's Return on Capital Employed over 5 years: stood at 8.23% in 2021, then plummeted by -86bps to 1.18% in 2022, then tumbled by -312bps to 2.5% in 2023, then plummeted by -195bps to 7.38% in 2024, then tumbled by -412bps to 37.8% in 2025.
  • Business Quant data shows Return on Capital Employed for VNDA at 37.8% in Q4 2025, 24.46% in Q3 2025, and 19.89% in Q2 2025.